Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

CYCCP

Cyclacel Pharmaceuticals (CYCCP)

Cyclacel Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CYCCP
DateHeureSourceTitreSymboleSociété
04/06/202414h00GlobeNewswire Inc.Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
03/06/202414h00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
17/05/202415h56Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202423h12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202422h05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
13/05/202422h05Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202403h56Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202403h53Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202403h52Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
06/05/202423h26Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
02/05/202422h30GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/04/202419h51AllPennyStocks.com$8 Million Private Placement Announcement Sends Biotech FlyingNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/04/202413h00GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
01/04/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
19/03/202421h05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
13/03/202421h05GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
07/03/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
06/03/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
20/02/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/02/202422h31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
31/01/202422h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/01/202415h15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical OfficerNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
10/01/202419h35Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
26/12/202315h28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
18/12/202315h00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP DeletionsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
12/12/202322h05GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Reverse Stock SplitNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/11/202315h15GlobeNewswire Inc.Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SECNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CYCCP

Dernières Valeurs Consultées

Delayed Upgrade Clock